{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:11:21Z","timestamp":1779297081610,"version":"3.51.4"},"reference-count":17,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune-checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab have improved outcomes in metastatic renal cell carcinoma (RCC) but can cause immune-related adverse events (irAEs), including potentially irreversible endocrine toxicities with long-term treatment implications. We present a 62-year-old man with metastatic clear-cell RCC who developed 3 distinct endocrine irAEs during ICI therapy: thyroiditis evolving into hypothyroidism, insulin-dependent diabetes mellitus with diabetic ketoacidosis, and secondary adrenal insufficiency (AI), necessitating ICI discontinuation. Additionally, he experienced immune-mediated inflammatory arthritis. His course required thyroid hormone replacement, insulin therapy, and hydrocortisone for AI. This case underscores the potential for sequential, multiglandular endocrine toxicities from ICIs, a phenomenon infrequently reported in the literature. Clinicians should remain vigilant for delayed or evolving presentations, even in the absence of autoantibodies or radiographic abnormalities. Early recognition, multidisciplinary management, and long-term follow-up are critical for ICI-associated endocrinopathies.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag024","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:43:14Z","timestamp":1769172194000},"source":"Crossref","is-referenced-by-count":1,"title":["Multigland dysfunction from immune-checkpoint inhibitors: a case of hypothyroidism, diabetes, and adrenal insufficiency"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7337-2565","authenticated-orcid":false,"given":"Ranjini","family":"Vengilote","sequence":"first","affiliation":[{"name":"Department of Medicine, Rochester General Hospital, Rochester Regional Health , Rochester, NY 14621 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oyiyechukwu","family":"Onwudiwe","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Rochester Regional Health , Rochester, NY 14607 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alshaima","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rochester General Hospital, Rochester Regional Health , Rochester, NY 14621 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0177-5908","authenticated-orcid":false,"given":"Michael","family":"Quartuccio","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Rochester Regional Health , Rochester, NY 14607 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"25","key":"2026022300265951200_luag024-B1","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026022300265951200_luag024-B2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"2026022300265951200_luag024-B3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"10","key":"2026022300265951200_luag024-B4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with Cancer Immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026022300265951200_luag024-B5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"10","key":"2026022300265951200_luag024-B6","first-page":"e46985","article-title":"Thyroid storm and type 1 diabetes Mellitus induced by combined ipilimumab and nivolumab immunotherapy: a case report","volume":"15","author":"Ramburuth","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"2026022300265951200_luag024-B7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2169\/internalmedicine.1268-18","article-title":"Nivolumab-induced hypophysitis, secondary adrenal insufficiency and destructive thyroiditis in a patient with lung adenocarcinoma","volume":"58","author":"Mishima","year":"2019","journal-title":"Internal medicine (Tokyo, Japan)"},{"key":"2026022300265951200_luag024-B8","doi-asserted-by":"crossref","first-page":"993622","DOI":"10.3389\/fimmu.2022.993622","article-title":"Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: a case report and review of literature","volume":"13","author":"Hino","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2026022300265951200_luag024-B9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1159\/000510044","article-title":"Type 1 diabetes, ACTH deficiency, and hypothyroidism simultaneously induced by nivolumab therapy in a patient with gastric cancer: a case report","volume":"13","author":"Marshall","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"11","key":"2026022300265951200_luag024-B10","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/cancers14112687","article-title":"Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment","volume":"14","author":"Chieng","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2026022300265951200_luag024-B11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","article-title":"American association of clinical endocrinology disease state clinical review: evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: a practical case-based clinical approach","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr Pract"},{"issue":"8","key":"2026022300265951200_luag024-B12","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"3","key":"2026022300265951200_luag024-B13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2026022300265951200_luag024-B14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects","volume":"50","author":"Martella","year":"2023","journal-title":"Semin Oncol"},{"issue":"36","key":"2026022300265951200_luag024-B15","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026022300265951200_luag024-B16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"2026022300265951200_luag024-B17","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/3\/luag024\/67067117\/luag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/3\/luag024\/67067117\/luag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:03Z","timestamp":1771824423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag024\/8494615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag024","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,23]]},"article-number":"luag024"}}